NCT04487912View on ClinicalTrials.gov

Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 24, 2020

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions
Breast CancerSentinel Lymph Node
Interventions
DRUG

Tilmanocept

Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept

DRUG

Nanocolloid

Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid

Trial Locations (1)

Unknown

university hospital, Ghent, Ghent

Sponsors

Collaborators (1)

Norgine
All Listed Sponsors
collaborator

Norgine

INDUSTRY

lead

University Hospital, Ghent

OTHER

NCT04487912 - Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer | Biotech Hunter | Biotech Hunter